A report by Frost & Sullivan predicts that positron emissiontomography's share of the worldwide market for cancer imagingand therapy equipment will grow rapidly in coming years. PET revenues will constitute 15% of the total market for suchequipment
A report by Frost & Sullivan predicts that positron emissiontomography's share of the worldwide market for cancer imagingand therapy equipment will grow rapidly in coming years.
PET revenues will constitute 15% of the total market for suchequipment by 2000, compared to 1% in 1993. PET's share of revenuesin the cancer imaging and therapy equipment market at that timewill match that of CT, which is expected to decline to 15%, comparedto 24% in 1993.
The market as a whole will grow at a 7% compound annual rate,from $2.74 billion in 1993 to $4.44 billion in 2000, accordingto the report, entitled World Cancer Diagnostic Imaging and TherapeuticEquipment Markets.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.